mitochondrial-derived 16-residue peptide

MOTS-c

US: Not on the registerEU: Not on the registerUK: Not on the registerCA: Not on the registerAU: Status unknownCH: Not on the registerBR: Not on the registerRS: Not on the registerSG: Not on the registerTR: Not on the register

Answer

MOTS-c is not authorised on any of the 10 registers read, and 1 of them holds no reading for it. No trial states a phase. It has 5 registered trials, 4 of them running.

RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov, read 2026-10-03

Not medical, legal or regulatory advice.

Registered trials5Trial register ClinicalTrials.gov

Running now4Trial register recruiting, active or enrolling

Results posted0Trial register with results on the register

Stopped early0%Trial register all peptides: 10%

5 trials by status

Trial register

Running 4Status unknown 1

ClinicalTrials.gov · read 2026-10-03 · 0 trials have posted results

Trials first submitted per year

Trial register

22019

12023

22026

ClinicalTrials.gov first-submitted date, last 3 years · read 2026-10-03. 2026 is not complete.

Status by jurisdiction

World map

CAISNOUSUKEUUACNKRJPMXCHLIRSTRINTHBREGILSAAESGARZAAUNZ

Authorised or registeredNot on the register, or withdrawnNot read yet, or status unknown

Where	Status	Register	Read
United States	Not on the register	FDA, openfda	2026-10-03
European Union	Not on the register	EMA, ema	2026-08-31
United Kingdom	Not on the register	MHRA, uk-mhra	2026-09-03
Canada	Not on the register	Health Canada, ca-dpd	2026-09-03
Australia	Status unknown	TGA, au-artg	not read
Switzerland	Not on the register	Swissmedic, ch-swissmedic	2026-09-03
Brazil	Not on the register	ANVISA, br-anvisa	2026-09-03
Serbia	Not on the register	ALIMS, rs-alims	2026-09-03
Singapore	Not on the register	HSA, sg-hsa	2026-09-03
Turkey	Not on the register	TITCK, tr-titck	2026-09-03

An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.

CHANGE ALERTS

Get an email when this changes

One email when the status of MOTS-c changes on the register. You confirm your address first.

ENFORCEMENT AND OFFICIAL ACTIONS

1 action by named authorities

Enforcement actions, board positions and payer rules that name MOTS-c, quoted from the source document. These are not approval decisions. This list shows the actions found so far. It is not a complete list: no authority publishes one.

US-OHenforcement

Ohio Board of Pharmacy, 2026-04-16

During the inspection, [redacted] was found to possess multiple vials of the following illegal dangerous drugs, in either a white powder, purple powder, or clear liquid form, intended for injection, which were obtained from an unlicensed, foreign source: l. MOTS-C 10mg, 5 vials; aa. MOTS-C 40mg, 4 vials;

State of Ohio Board of Pharmacy, Order, Case No. A-2026-0037, Findings of Fact paragraphs 2(l) and 2(aa) · quoted with the party redacted

REGISTERED TRIALS

5 trials, newest first

NCT07678073	Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels currently recruiting participants · register updated 2026-07-08
NCT07505745	MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity currently recruiting participants · register updated 2026-04-01
NCT03878706	The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination currently recruiting participants · register updated 2026-03-13
NCT06133946	Cohort Of DEafness-gene Screening running, but no longer enrolling · register updated 2023-11-18
NCT04027712	Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD last verified some time ago; the register no longer confirms its status · register updated 2019-07-23

All peptides · Method

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.